Camostat mesilate is not an effective treatment for mild to moderate SARS-CoV-2 infection, reports a study published in BMCMedicine.
Exploratory efficacy endpoints were the SARS-CoV-2 viral load , presence of lung lesions on chest imaging, time to resolution of clinical symptoms, proportion of patients in whom the clinical symptoms resolved, and antibody responses .
Safety evaluations included monitoring of adverse events, laboratory tests, vital signs, and 12-lead electrocardiography throughout the study.The objective of this study was to establish the superiority of camostat mesilate over placebo in patients with COVID-19 using the time to negative SARS-CoV-2 test as the primary endpoint.
A modified intention-to-treat analysis set was used for efficacy analyses by excluding any patients who tested negative for SARS-CoV-2 on day 1 . All analyses were performed on an as-randomized basis. The safety analysis set comprised all patients who received at least one dose of the allocated drug.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Q-LAAD: a dynamic, cost-effective rapid antigen test for detection of SARS-CoV-2Researchers developed a high-throughput, rapid antigen SARS-CoV-2 spike protein detection test using allonamers, a new type of aptamers that carry out allosteric regulation instead of catalytic activity.
Læs mere »
Food, vaccines, bacteria, and viruses may all prime our immune system to attack SARS-CoV-2Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, primarily causes mild to moderate upper-respiratory tract illness. However, some individuals with COVID-19 develop severe infections and require hospital admission.
Læs mere »
Study aims to understand how SARS-CoV-2 affects the brain long-termResearchers formulate a method to identify the molecular and systemic factors linking COVID-19 to short- and long-term neurologic illness.
Læs mere »
What are the differences in transmissibility between novel and emerging SARS-CoV-2 variants?What are the differences in transmissibility between novel and emerging SARS-CoV-2 variants? medrxivpreprint LSHTM Transmissibility COVID19 SARSCoV2 Variants
Læs mere »
Observing SARS-CoV-2 Omicron reinfections with different sub-variantsObserving SARS-CoV-2 Omicron reinfections with different sub-variants SARSCoV2 COVID19 Omicron Reinfection CDCgov
Læs mere »
COVID-19 cases, hospitalizations, and fatalities prevented by SARS-CoV-2 vaccination within the first 6 months after the vaccine became availableCOVID-19 cases, hospitalizations, and fatalities prevented by SARS-CoV-2 vaccination within the first 6 months after the vaccine became available medrxivpreprint Columbia ColumbiaMSPH COVID19 coronavirus covid vaccination vaccine SARSCoV2
Læs mere »